Metabolic abnormalities linked to an increased cardiovascular risk are associated with high-grade prostate cancer: a single biopsy cohort analysis.

Smoking, hypertension, abdominal obesity and metabolic abnormalities have been considered individual factors involved in prostate cancer (PCa) pathogenesis. All of these factors are used to define the individual cardiovascular risk (CVR).

The aim of our study was to evaluate the association between CVR and PCa diagnosis and grade among a consecutive series of men undergoing prostate biopsy.

From 2010 onwards, consecutive patients undergoing 12-core prostate biopsy were enrolled. Body mass index was measured before the biopsy. Blood samples were collected and tested for: PSA, fasting glucose, triglycerides and high-density lipoproteins. Blood pressure was also recorded. Metabolic syndrome was defined according to the Adult Treatment Panel III and CVR according to the European Association of Cardiologist Guidelines. We evaluated the association between CVR and PCa biopsy Gleason score using logistic regression analyses.

Five hundred and eighty-four patients were enrolled. Four hundred and six patients (70%) presented a moderate/high CVR. Two hundred and thirty-seven (40. 6%) patients had cancer on biopsy; 157 with moderate/high CVR and 80 with low/no CVR (P=0. 11). Out of the 237 patients with PCa, 113 had a Gleason score 6 and 124 a Gleason score ⩾7. Out of them, 92/124 (75%) presented a moderate/high CVR (P=0. 004). Moderate/high CVR was not associated with an increased risk of PCa (odds ratio (OR): 0. 741, confidence interval (CI): 0. 474-1. 156; P=0. 186) but with an increased risk of Gleason score ⩾7 (OR: 2. 154, CI: 1. 076-4. 314; P=0. 030).

In our study, a moderate/high CVR is associated with an increased risk of a high-grade Gleason score when PCa is diagnosed on biopsy. Although these results should be confirmed in multicentre studies, patients with moderate/high CVR should be carefully evaluated for PCa diagnosis. Prostate Cancer and Prostatic Diseases advance online publication, 6 October 2015; doi:10. 1038/pcan. 2015. 45.

Prostate cancer and prostatic diseases. 2015 Oct 06 [Epub ahead of print]

C De Nunzio, G Truscelli, A Trucchi, S Petta, M Tubaro, M Gacci, C Gaudio, F Presicce, A Tubaro

PubMed

Department of Urology, Ospedale Sant'Andrea, 'Sapienza' University of Rome, Rome, Italy. , Department of Heart and Great Vessels 'A. Reale', Policlinico Umberto I, ' Sapienza' University of Rome, Rome, Italy. , Department of Urology, Ospedale Sant'Andrea, 'Sapienza' University of Rome, Rome, Italy. , Department of Urology, Ospedale Sant'Andrea, 'Sapienza' University of Rome, Rome, Italy. , ICCU, Cardiovascular Department, Ospedale San Filippo Neri, Rome, Italy. , Department of Urology, Ospedale Careggi, University of Florence, Florence, Italy. , Department of Heart and Great Vessels 'A. Reale', Policlinico Umberto I, ' Sapienza' University of Rome, Rome, Italy. , Department of Urology, Ospedale Sant'Andrea, 'Sapienza' University of Rome, Rome, Italy. , Department of Urology, Ospedale Sant'Andrea, 'Sapienza' University of Rome, Rome, Italy.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe